Related Experiment Video
Updated: Jun 7, 2026
06:19
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis
1St. Jude Heritage Healthcare Foundation, Fullerton, California, USA. olmsteadjill@yahoo.com
Journal of the American Academy of Nurse Practitioners
|November 9, 2010
Summary
Nurse practitioners (NPs) can improve adherence to 5-aminosalicylic acid (5-ASA) for ulcerative colitis (UC) patients by addressing knowledge gaps and optimizing treatment. NPs play a key role in enhancing patient understanding and medication management.
Area of Science:
- Gastroenterology
- Pharmacology
- Nursing Practice
Background:
- 5-aminosalicylic acid (5-ASA) is a first-line treatment for ulcerative colitis (UC).
- Patient nonadherence to complex 5-ASA dosing regimens limits treatment efficacy.
- Understanding available formulations and NP roles is crucial for effective UC management.
Purpose of the Study:
- To update nurse practitioners (NPs) on 5-ASA formulations for UC.
- To explore the role of NPs in optimizing 5-ASA therapy for UC patients.
- To improve patient adherence and outcomes in UC treatment.
Main Methods:
- Literature search of Pubmed and conference abstracts.
- Focused on studies examining 5-ASA therapy in UC.
- Included research on the role of NPs in UC treatment.
Main Results:
- Patient adherence to 5-ASA regimens is frequently suboptimal.
- Lack of disease understanding or awareness of management options contributes to nonadherence.
- NPs are well-positioned to identify and overcome treatment barriers.
Conclusions:
- NPs are primary points of contact for UC patients.
- NPs can positively influence patient behavior and treatment adherence.
- Leveraging the NP-patient relationship enhances UC management and therapeutic success.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:26Peptic Ulcer Disease IV: Management
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...